This result is attributable to the advantages of anti‐inflammatory properties of insulin, that are associated with enhanced immune mediators and the reduction of proinflammatory cytokines, in addition to favorable glycemic control achieved by insulin that illustrated by Sardu et al.15who studies 25 diabetic COVID‐19 patients and found the average of the blood glucose during hospitalization was 10.65 ± 0.84 mmol/L in noninsulin‐treated compared to 7.69 ± 1.85 mmol/L in insulin‐treated groups (p < 0.001). The gene discussed is INS; the disease is COVID-19.